Danish pharmaceutical giant Lundbeck, which is one of several companies fined by the European Commission after an industry-wide probe, is slamming the regulator for fining the company on what it deems unreasonable grounds. The Commission raided Lundbeck offices in 2005 and then fined the company for making anticompetitive agreements with other pharmaceutical companies that barred them from producing generic forms of ones of Lundbeck’s most popular drugs. While the company claims those agreements were legal, and that it had the right to make those contracts while key patent lawsuits were being decided, the European Commission is fighting pharmaceutical companies against such so-called pay-for-delay schemes. Lundbeck is currently speaking out against the regulator for fining the company and modifying its accusations after the company sent a statement of objections concerning the Commission’s ruling.
Full Content: European Voice
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI